NeuroEM is a medical device company pioneering a non-pharmaceutical approach to Alzheimer’s treatment through its patented TEMT-RF platform and wearable MemorEM device. The technology has received FDA Breakthrough Device Designation for wellness and is designed to disaggregate toxic proteins within neurons. The company is led by CEO Chuck Papageorgiou. Lunch Pail Ventures invested in NeuroEM Therapeutics in August 2025.